ArticlePLOS global public health2024
Contextual factors influencing schistosomiasis treatment and identification of delivery platforms for arpraziquantel in hard-to-reach areas and populations in Homa Bay County, Kenya.
Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new formulation of praziquantel, arpraziquantel (arPZQ), has been developed for preschool-aged children (PSAC) to fill the treatment gap for this age group in schistosomiasis control and elimination programs. There is now a priority to ensure that the drug reaches all at-risk PSAC in endemic areas, including hard-to-reach areas and populations. This study aimed to determine schistosomiasis treatment-related contextual factors among fishermen and island populations in Homa Bay County, Kenya, and to identify a suitable platform to deliver arPZQ. We conducted a generic qualitative study using two case study interviews with parents/caregivers living with disability caring for children ≤5 years,18 focus group discussions (FGDs) with parents/caregivers of children ≤5 years (each with 8-10 participants), 14 key informant interviews (KIIs) with various government agencies, and unstructured observations. The data were analyzed using thematic analysis. The case study interviews and FGDs revealed awareness of schistosomiasis among community members but limited knowledge of transmission risk factors. Lake water and open defecation were the main predisposing factors to infection. We observed poor health-seeking behavior in the community due to inaccessibility of quality healthcare services, resulting from health system level, population level, and geographic barriers. Despite these barriers, community members reported positive experiences with previous PZQ mass drug administration (MDAs) and other innovative healthcare programs, and expressed willingness to participate in future MDAs, including with arPZQ. Based on the reported barriers, the door-to-door distribution approach by community health promoters was proposed by parents and key informants as the most feasible platform for community sensitization, mobilization, and arPZQ delivery. To achieve high arPZQ treatment coverage for all at-risk PSAC, and promote ownership and sustainability of the program, the door-to-door approach is the most promising platform to deliver treatment and public health promotion in marginalized hard-to-reach island populations of Lake Victoria, Kenya.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.